IDEXX Laboratories (NASDAQ: IDXX) and BG Medicine (OTCMKTS:BGMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility & Risk

How to Become a New Pot Stock Millionaire

IDEXX Laboratories has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, BG Medicine has a beta of 3.31, meaning that its stock price is 231% more volatile than the S&P 500.

Profitability

This table compares IDEXX Laboratories and BG Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IDEXX Laboratories 13.36% -432.19% 17.19%
BG Medicine N/A N/A N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IDEXX Laboratories and BG Medicine, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories 1 0 5 0 2.67
BG Medicine 0 0 0 0 N/A

IDEXX Laboratories currently has a consensus target price of $190.67, indicating a potential downside of 4.05%. Given IDEXX Laboratories’ higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than BG Medicine.

Earnings & Valuation

This table compares IDEXX Laboratories and BG Medicine’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IDEXX Laboratories $1.97 billion 8.79 $263.14 million $3.28 60.59
BG Medicine $1.57 million 0.29 -$5.30 million N/A N/A

IDEXX Laboratories has higher revenue and earnings than BG Medicine.

Institutional and Insider Ownership

87.5% of IDEXX Laboratories shares are held by institutional investors. 2.6% of IDEXX Laboratories shares are held by insiders. Comparatively, 6.5% of BG Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

IDEXX Laboratories beats BG Medicine on 8 of the 11 factors compared between the two stocks.

About IDEXX Laboratories

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

About BG Medicine

BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.